Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ATOS
ATOS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ATOS News
Atossa Therapeutics Closes Direct Offering Raising $4.5 Million
Jun 12 2026
PRnewswire
Atossa Therapeutics Closes Direct Offering Raising $4.5 Million
Jun 12 2026
Newsfilter
Atossa Therapeutics Secures $16.5 Million Securities Purchase Agreement
Jun 11 2026
NASDAQ.COM
Atossa Therapeutics Announces Direct Offering for $16.5M
Jun 11 2026
seekingalpha
Atossa Therapeutics Secures $4.5 Million Financing with Potential for $12 Million
Jun 11 2026
PRnewswire
Atossa Presents New Data Highlighting (Z)-Endoxifen's Potential in Breast Cancer
May 27 2026
PRnewswire
Atossa Presents Robust ER Inhibition Data for (Z)-Endoxifen in Breast Cancer
May 27 2026
Newsfilter
Atossa's New Research Findings on DMD Treatment
May 20 2026
Newsfilter
Atossa's New Research Findings on DMD
May 20 2026
PRnewswire
Atossa Hosts Key Opinion Leader Event on (Z)-Endoxifen
May 14 2026
PRnewswire
Atossa Therapeutics Q1 Financial Results
May 08 2026
seekingalpha
Atossa Therapeutics Reports Q1 2026 Financial Results and Updates
May 08 2026
PRnewswire
Atossa Announces KARISMA Trial Results for Endoxifen in Breast Cancer Prevention
May 06 2026
PRnewswire
Atossa Reports Positive Results from Endoxifen Clinical Trial for Breast Cancer Risk Reduction
May 06 2026
Newsfilter
Atossa's Drug Receives Rare Pediatric Disease Designation
May 04 2026
stocktwits
Atossa Secures Rare Pediatric Disease Designation for (Z)-endoxifen
May 04 2026
PRnewswire
Show More News
